Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.64 USD
Change Today -0.01 / -1.54%
Volume 5.2K
As of 3:58 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

emisphere technologies inc (EMIS) Snapshot

Open
$0.65
Previous Close
$0.65
Day High
$0.65
Day Low
$0.64
52 Week High
06/26/15 - $0.90
52 Week Low
12/29/14 - $0.20
Market Cap
38.8M
Average Volume 10 Days
66.2K
EPS TTM
$-0.79
Shares Outstanding
60.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EMISPHERE TECHNOLOGIES INC (EMIS)

emisphere technologies inc (EMIS) Related Bloomberg News

View More Bloomberg News

emisphere technologies inc (EMIS) Related Businessweek News

No Related Businessweek News Found

emisphere technologies inc (EMIS) Details

Emisphere Technologies, Inc. operates as a commercial stage specialty pharmaceutical company in the United States. It offers Oral Eligen B12 Rx, an oral formulation medical food for use by B12 deficient individuals. The company is also developing GLP-1 (glucagon-like peptide-1), which is in Phase II clinical trial for the treatment for type 2 diabetes. Its preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. The company has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk’s insulin using the company’s Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is headquartered in Roseland, New Jersey.

10 Employees
Last Reported Date: 03/31/15
Founded in 1986

emisphere technologies inc (EMIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $650.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Vice President of Sales and Marketing
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2014.

emisphere technologies inc (EMIS) Key Developments

Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Emisphere Technologies, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues for the first quarter ended March 31, 2015 were $6,000, compared to $0 revenue recognized in the first quarter ended March 31, 2014. The increase was primarily due to the commercialization of Eligen B12 which was launched in March 2015. The company reported a net loss of $33 million, or $0.54 per basic and diluted share, compared to net loss of $3.4 million, or $0.06 per basic and diluted share, for the same prior year period. Operating loss was $4.668 million against $2.345 million a year ago. Loss before income tax benefit was $32.968 million against $5.042 million a year ago.

Emisphere Technologies, Inc. to Report Q1, 2015 Results on May 15, 2015

Emisphere Technologies, Inc. announced that they will report Q1, 2015 results at 8:30 AM, Eastern Daylight on May 15, 2015

Emisphere Technologies, Inc., Q1 2015 Earnings Call, May 15, 2015

Emisphere Technologies, Inc., Q1 2015 Earnings Call, May 15, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EMIS:US $0.64 USD -0.01

EMIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $5.95 USD +0.49
Boston Scientific Corp $17.51 USD +0.40
CR Bard Inc $192.95 USD +2.81
Johnson & Johnson $99.02 USD +0.74
Medtronic PLC $77.47 USD +1.81
View Industry Companies
 

Industry Analysis

EMIS

Industry Average

Valuation EMIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6,574.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMISPHERE TECHNOLOGIES INC, please visit www.emisphere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.